Table 1.
Pharmacy Forecast Panelists’ Predictions of Operational Changes in Their Markets by 201811
| Description | Very Likely | Somewhat Likely | Somewhat Unlikely | Very Unlikely |
|---|---|---|---|---|
| Pharmacy departments in at least 50% of hospitals will be responsible for compounding all high-risk sterile products needed by the hospitals’ patients (versus outsourcing this function). | 30% | 31% | 29% | 10% |
| At least 25% of hospital-based sterile compounding operations will be accredited by a quality-improvement organization that has a specific program for sterile compounding (e.g., Pharmacy Compounding Accreditation Board). | 29% | 48% | 20% | 3% |
| At least 25% of hospital-based sterile compounding operations will contract to provide this service to other hospitals. | 21% | 44% | 22% | 13% |
| At least 50% of health systems will conduct centralized drug preparation, repackaging, and distribution for multiple hospitals within their system. | 42% | 39% | 15% | 4% |
| In at least 25% of hospitals, individuals employed by the pharmacy department will be responsible for administration of medications to patients and for documentation of administration. | 3% | 12% | 41% | 44% |
| At least 50% of small hospitals (50 or fewer beds) will have a contractual relationship with a pharmacy department of a larger institution to provide operational advice and support (including after-hours order verification). | 39% | 44% | 16% | 2% |
| The P&T committee in at least 50% of hospitals will have a formal process for evaluating biosimilars. | 42% | 48% | 7% | 3% |
| At least 75% of hospitals will require conflict-of-interest disclosures by members of P&T committees and by clinicians who propose new agents for formulary addition. | 76% | 18% | 5% | 1% |